Susquehanna International Group
VYGR icon

Susquehanna International Group’s Voyager Therapeutics VYGR Stock Holding History

Susquehanna International Group’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$137K Buy
35,400
+19,900
+128% +$78.3K ﹤0.01% 12105
2025
Q4 		$60.9K Sell
15,500
-700
-4% -$3.1K ﹤0.01% 11686
2025
Q3 		$75.7K Sell
16,200
-6,500
-29% -$23.5K ﹤0.01% 11705
2025
Q2 		$70.6K Buy
+22,700
New +$73.2K ﹤0.01% 11986
2025
Q1 		– Sell
-37,400
Closed -$212K – 13557
2024
Q4 		$212K Buy
37,400
+11,600
+45% +$74.8K ﹤0.01% 10609
2024
Q3 		$151K Buy
25,800
+5,400
+26% +$39.3K ﹤0.01% 10738
2024
Q2 		$161K Sell
20,400
-16,500
-45% -$138K ﹤0.01% 10612
2024
Q1 		$344K Buy
36,900
+19,600
+113% +$165K ﹤0.01% 9394
2023
Q4 		$146K Sell
17,300
-40,800
-70% -$296K ﹤0.01% 11001
2023
Q3 		$450K Buy
58,100
+31,100
+115% +$284K ﹤0.01% 8482
2023
Q2 		$309K Sell
27,000
-131,000
-83% -$1.36M ﹤0.01% 9374
2023
Q1 		$1.22M Buy
+158,000
New +$1.26M ﹤0.01% 6295
2022
Q4 		– Sell
-55,300
Closed -$327K – 13805
2022
Q3 		$327K Sell
55,300
-15,500
-22% -$99.2K ﹤0.01% 9574
2022
Q2 		$418K Sell
70,800
-6,900
-9% -$46.6K ﹤0.01% 8715
2022
Q1 		$592K Sell
77,700
-27,400
-26% -$122K ﹤0.01% 8535
2021
Q4 		$285K Buy
105,100
+86,300
+459% +$294K ﹤0.01% 10610
2021
Q3 		$49K Sell
18,800
-26,600
-59% -$86.4K ﹤0.01% 12355
2021
Q2 		$188K Sell
45,400
-106,500
-70% -$483K ﹤0.01% 11658
2021
Q1 		$715K Buy
151,900
+74,700
+97% +$509K ﹤0.01% 8603
2020
Q4 		$552K Buy
+77,200
New +$742K ﹤0.01% 8068
2019
Q3 		– Sell
-21,700
Closed -$591K – 10915
2019
Q2 		$591K Buy
21,700
+6,000
+38% +$137K ﹤0.01% 6928
2019
Q1 		$300K Buy
+15,700
New +$205K ﹤0.01% 7214
2018
Q4 		– Sell
-27,700
Closed -$524K – 10076
2018
Q3 		$524K Sell
27,700
-6,300
-19% -$121K ﹤0.01% 6430
2018
Q2 		$664K Sell
34,000
-34,300
-50% -$678K ﹤0.01% 6235
2018
Q1 		$1.28M Buy
68,300
+1,900
+3% +$41.1K ﹤0.01% 4734
2017
Q4 		$1.1M Buy
+66,400
New +$1.14M ﹤0.01% 5028

Other funds holding VYGR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Susquehanna International Group's VYGR Position: Q1 2026 in Review

Susquehanna International Group increased its Voyager Therapeutics (VYGR) stake by 21% in Q1 2026, buying an estimated $54K and bringing the position to 78,891 shares worth $305K. The position accounts for ﹤0.01% of the portfolio, ranked #10813.

Susquehanna International Group first reported a position in VYGR in Q4 2016 and has held it in 31 quarters since. The position peaked at $2.48M in Q1 2023. 135 funds tracked by Wall St. Rank hold VYGR as of Q1 2026.

  • Susquehanna International Group held 78,891 shares of Voyager Therapeutics worth $305K as of Q1 2026.
  • Susquehanna International Group bought 13,709 Voyager Therapeutics shares in Q1 2026, an estimated $54K.
  • Voyager Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #10813 holding.
  • Susquehanna International Group first reported a position in Voyager Therapeutics in Q4 2016 and has held it in 31 quarters since.
  • Susquehanna International Group's Voyager Therapeutics position peaked at $2.48M in Q1 2023.
  • 135 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.